ReShape Lifesciences has announced preclinical research demonstrating the its investigational Diabetes Bloc-Stim Neuromodulation (DBSN) proprietary device for the treatment of type 2 diabetes mellitus (T2DM) was well-tolerated and met the study endpoints. The study was conducted as a part of the National Institutes of Health (NIH) Small Business Innovation Research Phase I grant that was previously awarded in August 2019.
"The ReShape Lifesciences Diabetes Bloc-Stim Neuromodulation technology has accomplished key goals through the NIH Phase I Small Business Innovation Research grant study. The preliminary data strongly calls for pursuit of further evaluating this treatment for type 2 diabetes mellitus," said Dr Charles Billington, Chief of Endocrinology at the VA Medical Center in Minneapolis, MN, and Professor of Medicine at the University of Minnesota, and the lead advisor in the ReShape Lifesciences preclinical diabetes research programme.
The preclinical investigation consisted of simultaneous electrical blockade and stimulation of individual vagal nerve branches and was conducted in a type 2 diabetic porcine animal model. Results showed a significant reduction of blood glucose and histopathology of organ systems effected by the neuromodulation demonstrated healthy tissue. These findings broaden the proof-of-concept and mechanism of action, results of which were initially presented at ObesityWeek 2018. Further demonstrating that dual vagus nerve neuromodulation, a novel and proprietary approach, improves glycaemic control in animal models of T2DM.
"Bioelectronic medicine represents a growing and exciting field as it supports the potential for less dependence on drug therapy and addresses the challenges associated with daily compliance for those suffering from diabetes," said Bart Bandy, President & CEO of ReShape Lifesciences Inc. "Our exploration of neuromodulation for diabetes aligns with the ReShape Lifesciences corporate strategy to build our portfolio and pipeline with technologies and services that improve the treatment of obesity and metabolic diseases. Based on these positive outcomes, the preclinical study represents a successful completion of the NIH Phase I grant and we look forward to advancing this unique diabetes focused innovation."